Calendar

Here 24/7 Wall St. takes a look at a recent report by Canaccord Genuity regarding to biotech and pharmaceutical companies expecting updates to their drug pipeline or other major events for the rest...
  This last week was a crazy end to the October selling craze being followed by a flood of stock buying this week prior to Friday’s major profit taking. Some of that buying is obviously...
24/7 Wall St. has come up with its own view on earnings season by sector, along with relative performance on the top exchange traded funds for those sectors.
Here 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the remainder of October.
We wouldn't want our readers thinking we were just taking time off to sit in the sun or in the rain. Here are more than 25 issues concerning your money and interests.
Here is a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of October.
With 2018 coming to a close in just a few months, Merrill Lynch is taking a close look at the biotech industry and what key catalysts to expect before 2019.
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in September.
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates in July.
Merck shares retreated to start off the week despite the announcement of good news from the FDA.
Here are a few biotech and pharmaceutical companies to watch for in the coming week and for the month of July.
Here, 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and the rest of June.
Here 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and the rest of June.
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates in May.
Here is a 24/7 Wall St. calendar with a few of the biggest biotech and pharmaceutical companies expecting clinical trial and FDA updates in April.